| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Caliciviridae Infections | 77 | 2025 | 328 | 15.210 |
Why?
|
| Norovirus | 85 | 2025 | 317 | 14.800 |
Why?
|
| Gastroenteritis | 56 | 2025 | 349 | 7.690 |
Why?
|
| Antibodies, Viral | 63 | 2025 | 1153 | 6.540 |
Why?
|
| Viral Vaccines | 25 | 2025 | 337 | 6.510 |
Why?
|
| Influenza Vaccines | 40 | 2025 | 482 | 5.980 |
Why?
|
| Influenza, Human | 46 | 2025 | 662 | 5.700 |
Why?
|
| Norwalk virus | 32 | 2024 | 170 | 5.320 |
Why?
|
| Blood Group Antigens | 21 | 2025 | 73 | 4.520 |
Why?
|
| Antibodies, Neutralizing | 16 | 2025 | 470 | 3.560 |
Why?
|
| Vaccines, Virus-Like Particle | 10 | 2024 | 33 | 3.430 |
Why?
|
| Respiratory Tract Infections | 15 | 2024 | 274 | 2.370 |
Why?
|
| Immunogenicity, Vaccine | 9 | 2025 | 106 | 2.230 |
Why?
|
| Virus Replication | 23 | 2025 | 607 | 2.140 |
Why?
|
| Vaccination | 21 | 2025 | 963 | 1.860 |
Why?
|
| Disease Outbreaks | 17 | 2019 | 320 | 1.800 |
Why?
|
| Genotype | 22 | 2024 | 2565 | 1.780 |
Why?
|
| Immunoglobulin A | 11 | 2019 | 207 | 1.640 |
Why?
|
| Adjuvants, Immunologic | 17 | 2025 | 382 | 1.590 |
Why?
|
| Antibodies, Blocking | 5 | 2024 | 61 | 1.490 |
Why?
|
| Influenza A virus | 16 | 2020 | 139 | 1.440 |
Why?
|
| Organoids | 11 | 2025 | 281 | 1.440 |
Why?
|
| Shellfish | 12 | 2022 | 31 | 1.420 |
Why?
|
| Humans | 251 | 2025 | 125189 | 1.420 |
Why?
|
| Adult | 109 | 2025 | 29628 | 1.310 |
Why?
|
| Feces | 26 | 2023 | 727 | 1.260 |
Why?
|
| Vaccines, Inactivated | 20 | 2025 | 145 | 1.230 |
Why?
|
| Virus Cultivation | 9 | 2024 | 76 | 1.230 |
Why?
|
| Young Adult | 45 | 2025 | 9053 | 1.220 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 9 | 2021 | 61 | 1.200 |
Why?
|
| Cross Infection | 9 | 2019 | 325 | 1.180 |
Why?
|
| Antiviral Agents | 14 | 2025 | 753 | 1.180 |
Why?
|
| Double-Blind Method | 24 | 2023 | 1637 | 1.160 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 6 | 2025 | 29 | 1.120 |
Why?
|
| Immunization, Secondary | 11 | 2025 | 104 | 1.070 |
Why?
|
| Immunocompromised Host | 6 | 2019 | 294 | 1.040 |
Why?
|
| Middle Aged | 70 | 2025 | 26927 | 1.010 |
Why?
|
| Virus Attachment | 10 | 2021 | 41 | 1.010 |
Why?
|
| Ostreidae | 15 | 2013 | 27 | 1.000 |
Why?
|
| Antigens, Viral | 11 | 2021 | 439 | 0.980 |
Why?
|
| Hemagglutination Inhibition Tests | 19 | 2025 | 114 | 0.970 |
Why?
|
| Immunoglobulin G | 12 | 2023 | 777 | 0.950 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 18 | 2014 | 1290 | 0.890 |
Why?
|
| Intestinal Mucosa | 7 | 2025 | 778 | 0.860 |
Why?
|
| Schistosomiasis mansoni | 1 | 2023 | 24 | 0.830 |
Why?
|
| Host-Pathogen Interactions | 6 | 2025 | 253 | 0.810 |
Why?
|
| Male | 103 | 2025 | 61525 | 0.810 |
Why?
|
| Polymerase Chain Reaction | 14 | 2016 | 1586 | 0.810 |
Why?
|
| Female | 104 | 2025 | 66806 | 0.780 |
Why?
|
| Single-Chain Antibodies | 4 | 2020 | 44 | 0.770 |
Why?
|
| Adolescent | 55 | 2025 | 19363 | 0.760 |
Why?
|
| Polysaccharides | 6 | 2021 | 140 | 0.750 |
Why?
|
| Picornaviridae Infections | 4 | 2011 | 48 | 0.750 |
Why?
|
| RNA, Viral | 17 | 2016 | 536 | 0.750 |
Why?
|
| Injections, Intramuscular | 13 | 2025 | 194 | 0.740 |
Why?
|
| Neutralization Tests | 10 | 2024 | 235 | 0.740 |
Why?
|
| Smallpox Vaccine | 5 | 2021 | 37 | 0.740 |
Why?
|
| Saliva | 3 | 2019 | 114 | 0.720 |
Why?
|
| Seasons | 8 | 2023 | 312 | 0.710 |
Why?
|
| Lipid A | 3 | 2019 | 23 | 0.700 |
Why?
|
| Antibodies, Monoclonal | 7 | 2020 | 1033 | 0.700 |
Why?
|
| Influenza B virus | 8 | 2023 | 87 | 0.690 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 3 | 2012 | 11 | 0.670 |
Why?
|
| Virus Diseases | 8 | 2008 | 280 | 0.670 |
Why?
|
| B-Lymphocytes | 4 | 2017 | 534 | 0.660 |
Why?
|
| Neuraminidase | 7 | 2025 | 36 | 0.660 |
Why?
|
| Receptors, Virus | 7 | 2019 | 107 | 0.650 |
Why?
|
| Anti-Infective Agents | 1 | 2022 | 265 | 0.650 |
Why?
|
| Glucosides | 1 | 2019 | 47 | 0.630 |
Why?
|
| Schistosomiasis | 1 | 2019 | 50 | 0.630 |
Why?
|
| Antibodies, Helminth | 1 | 2019 | 125 | 0.630 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 6 | 2023 | 178 | 0.600 |
Why?
|
| Rotavirus | 7 | 2023 | 497 | 0.600 |
Why?
|
| Viral Nonstructural Proteins | 4 | 2018 | 191 | 0.590 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 6 | 2020 | 115 | 0.590 |
Why?
|
| Rhinovirus | 7 | 2015 | 59 | 0.580 |
Why?
|
| Cross Reactions | 3 | 2014 | 192 | 0.580 |
Why?
|
| Stem Cells | 4 | 2021 | 707 | 0.580 |
Why?
|
| Healthy Volunteers | 6 | 2024 | 133 | 0.570 |
Why?
|
| Immunization Schedule | 7 | 2024 | 102 | 0.560 |
Why?
|
| Epithelial Cells | 3 | 2019 | 909 | 0.560 |
Why?
|
| Virus Shedding | 4 | 2023 | 80 | 0.550 |
Why?
|
| Intestines | 7 | 2024 | 577 | 0.550 |
Why?
|
| Adenosine Monophosphate | 3 | 2021 | 42 | 0.530 |
Why?
|
| Capsid Proteins | 10 | 2023 | 184 | 0.530 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 7 | 2025 | 59 | 0.530 |
Why?
|
| Bile Acids and Salts | 4 | 2024 | 244 | 0.530 |
Why?
|
| Placebos | 9 | 2016 | 241 | 0.520 |
Why?
|
| Alanine | 3 | 2021 | 187 | 0.520 |
Why?
|
| Virion | 9 | 2017 | 147 | 0.510 |
Why?
|
| Vaccines, Attenuated | 7 | 2021 | 175 | 0.500 |
Why?
|
| Peptide Hydrolases | 4 | 2021 | 145 | 0.490 |
Why?
|
| United States | 20 | 2024 | 10915 | 0.480 |
Why?
|
| Animals | 57 | 2024 | 34232 | 0.480 |
Why?
|
| Hepatovirus | 5 | 2001 | 17 | 0.470 |
Why?
|
| Vaccines | 1 | 2019 | 365 | 0.460 |
Why?
|
| Polysorbates | 5 | 2025 | 27 | 0.450 |
Why?
|
| Diarrhea | 8 | 2023 | 317 | 0.440 |
Why?
|
| ABO Blood-Group System | 6 | 2010 | 66 | 0.420 |
Why?
|
| Hemagglutination, Viral | 2 | 2015 | 10 | 0.420 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 293 | 0.410 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 12 | 2017 | 824 | 0.410 |
Why?
|
| Virus Internalization | 3 | 2023 | 55 | 0.410 |
Why?
|
| Jejunum | 3 | 2024 | 127 | 0.410 |
Why?
|
| Vaccines, Synthetic | 8 | 2025 | 316 | 0.410 |
Why?
|
| Hospitalization | 6 | 2020 | 1783 | 0.400 |
Why?
|
| Aged | 34 | 2022 | 19870 | 0.390 |
Why?
|
| Squalene | 4 | 2025 | 24 | 0.390 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2021 | 20 | 0.380 |
Why?
|
| Picornaviridae | 1 | 2011 | 20 | 0.380 |
Why?
|
| Histocompatibility Antigens | 2 | 2024 | 19 | 0.380 |
Why?
|
| Vaccinia | 1 | 2021 | 8 | 0.380 |
Why?
|
| Schistosoma mansoni | 2 | 2023 | 24 | 0.370 |
Why?
|
| Fluoroimmunoassay | 1 | 2011 | 6 | 0.370 |
Why?
|
| Vaccines, DNA | 1 | 2021 | 48 | 0.370 |
Why?
|
| Advisory Committees | 6 | 2022 | 152 | 0.370 |
Why?
|
| Ebola Vaccines | 2 | 2022 | 17 | 0.370 |
Why?
|
| Antibody Formation | 8 | 2021 | 266 | 0.370 |
Why?
|
| Immunity, Cellular | 4 | 2021 | 206 | 0.370 |
Why?
|
| Viral Proteins | 6 | 2021 | 347 | 0.360 |
Why?
|
| Influenza A Virus, H7N7 Subtype | 3 | 2020 | 11 | 0.350 |
Why?
|
| Hemorrhagic Fever, Ebola | 2 | 2022 | 58 | 0.350 |
Why?
|
| Caliciviridae | 2 | 2001 | 19 | 0.350 |
Why?
|
| Communicable Diseases | 3 | 2022 | 161 | 0.340 |
Why?
|
| DNA Primers | 8 | 2013 | 657 | 0.340 |
Why?
|
| Sensitivity and Specificity | 14 | 2016 | 2057 | 0.330 |
Why?
|
| Lung Diseases, Obstructive | 2 | 2000 | 34 | 0.330 |
Why?
|
| Vaccines, Combined | 3 | 2023 | 39 | 0.320 |
Why?
|
| Interferons | 3 | 2020 | 125 | 0.320 |
Why?
|
| Administration, Intranasal | 4 | 2015 | 132 | 0.300 |
Why?
|
| Immunoassay | 5 | 2016 | 130 | 0.300 |
Why?
|
| Klebsiella Infections | 2 | 2021 | 54 | 0.300 |
Why?
|
| Peptide Library | 4 | 2017 | 57 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 734 | 0.300 |
Why?
|
| Virology | 4 | 2013 | 31 | 0.300 |
Why?
|
| Spike Glycoprotein, Coronavirus | 3 | 2025 | 188 | 0.290 |
Why?
|
| Child | 20 | 2025 | 24421 | 0.290 |
Why?
|
| Cohort Studies | 7 | 2021 | 4817 | 0.290 |
Why?
|
| Aluminum Hydroxide | 2 | 2023 | 41 | 0.290 |
Why?
|
| Bivalvia | 4 | 2001 | 15 | 0.280 |
Why?
|
| Acinetobacter Infections | 1 | 2007 | 26 | 0.280 |
Why?
|
| Rotavirus Infections | 3 | 2023 | 354 | 0.270 |
Why?
|
| Acinetobacter baumannii | 1 | 2007 | 37 | 0.270 |
Why?
|
| Influenza in Birds | 2 | 2020 | 27 | 0.270 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2010 | 604 | 0.270 |
Why?
|
| Food Microbiology | 4 | 2013 | 24 | 0.270 |
Why?
|
| Fucose | 2 | 2024 | 21 | 0.260 |
Why?
|
| Travel | 3 | 2014 | 115 | 0.260 |
Why?
|
| Gastrointestinal Diseases | 2 | 2021 | 339 | 0.260 |
Why?
|
| Models, Molecular | 7 | 2021 | 1079 | 0.260 |
Why?
|
| Fucosyltransferases | 4 | 2021 | 29 | 0.250 |
Why?
|
| Biomarkers | 1 | 2015 | 3091 | 0.250 |
Why?
|
| Time Factors | 11 | 2023 | 6338 | 0.250 |
Why?
|
| Vaccinia virus | 3 | 2021 | 52 | 0.240 |
Why?
|
| Escherichia coli | 7 | 2024 | 985 | 0.240 |
Why?
|
| Francisella tularensis | 3 | 2017 | 15 | 0.240 |
Why?
|
| Trisaccharides | 1 | 2025 | 7 | 0.240 |
Why?
|
| Pyrazoles | 3 | 2024 | 305 | 0.230 |
Why?
|
| Antibodies, Bacterial | 6 | 2017 | 389 | 0.230 |
Why?
|
| Viruses | 3 | 2017 | 122 | 0.220 |
Why?
|
| Interferon Type I | 3 | 2016 | 107 | 0.220 |
Why?
|
| Azetidines | 2 | 2022 | 58 | 0.220 |
Why?
|
| Gammaproteobacteria | 1 | 2024 | 16 | 0.220 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2024 | 62 | 0.220 |
Why?
|
| Purines | 2 | 2022 | 116 | 0.220 |
Why?
|
| Base Sequence | 10 | 2014 | 3103 | 0.220 |
Why?
|
| Bacterial Vaccines | 2 | 2017 | 99 | 0.210 |
Why?
|
| Bile | 2 | 2021 | 46 | 0.210 |
Why?
|
| Epitopes | 4 | 2023 | 433 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 7 | 2022 | 2431 | 0.210 |
Why?
|
| Molecular Sequence Data | 12 | 2014 | 3892 | 0.210 |
Why?
|
| Sapovirus | 1 | 2023 | 6 | 0.210 |
Why?
|
| Sequence Analysis, DNA | 6 | 2016 | 1755 | 0.210 |
Why?
|
| Culture Techniques | 1 | 2023 | 89 | 0.210 |
Why?
|
| Antibodies | 2 | 2016 | 374 | 0.210 |
Why?
|
| Amino Acid Sequence | 9 | 2020 | 2714 | 0.210 |
Why?
|
| Virulence Factors | 2 | 2016 | 173 | 0.210 |
Why?
|
| Serologic Tests | 3 | 2014 | 118 | 0.210 |
Why?
|
| Orthomyxoviridae | 3 | 1999 | 51 | 0.210 |
Why?
|
| Brazil | 1 | 2023 | 122 | 0.200 |
Why?
|
| Hydroxylamines | 1 | 2022 | 4 | 0.200 |
Why?
|
| Cytidine | 1 | 2022 | 9 | 0.200 |
Why?
|
| Rotavirus Vaccines | 1 | 2023 | 72 | 0.200 |
Why?
|
| Biological Assay | 2 | 2015 | 104 | 0.200 |
Why?
|
| Infant | 16 | 2024 | 12516 | 0.200 |
Why?
|
| Sulfonamides | 2 | 2022 | 271 | 0.200 |
Why?
|
| Asthma | 5 | 2006 | 756 | 0.200 |
Why?
|
| Protozoan Vaccines | 1 | 2023 | 96 | 0.190 |
Why?
|
| Ritonavir | 1 | 2022 | 54 | 0.190 |
Why?
|
| Protein Binding | 8 | 2021 | 1756 | 0.190 |
Why?
|
| Disinfectants | 1 | 2022 | 25 | 0.190 |
Why?
|
| Dengue Vaccines | 1 | 2021 | 13 | 0.190 |
Why?
|
| Child, Preschool | 13 | 2021 | 14027 | 0.190 |
Why?
|
| Aged, 80 and over | 8 | 2022 | 6598 | 0.190 |
Why?
|
| Interferon beta-1a | 1 | 2021 | 18 | 0.190 |
Why?
|
| Glycoproteins | 1 | 2024 | 370 | 0.190 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 64 | 0.190 |
Why?
|
| Intestine, Small | 2 | 2023 | 307 | 0.180 |
Why?
|
| Cell Line | 10 | 2018 | 2756 | 0.180 |
Why?
|
| Immunization | 5 | 2021 | 307 | 0.180 |
Why?
|
| Carbohydrate Metabolism | 2 | 2019 | 57 | 0.180 |
Why?
|
| Yellow Fever | 1 | 2021 | 75 | 0.180 |
Why?
|
| Bacteriuria | 1 | 2022 | 82 | 0.180 |
Why?
|
| Bacterial Proteins | 2 | 2016 | 890 | 0.180 |
Why?
|
| Immunologic Tests | 1 | 2001 | 19 | 0.180 |
Why?
|
| Cell Membrane | 1 | 2023 | 462 | 0.180 |
Why?
|
| Immunomagnetic Separation | 1 | 2000 | 13 | 0.180 |
Why?
|
| Pregnancy | 8 | 2024 | 7207 | 0.180 |
Why?
|
| Kava | 1 | 2020 | 7 | 0.180 |
Why?
|
| Glycosphingolipids | 1 | 2020 | 11 | 0.180 |
Why?
|
| Cystitis | 1 | 2021 | 49 | 0.180 |
Why?
|
| Occupational Exposure | 1 | 2022 | 128 | 0.180 |
Why?
|
| Klebsiella pneumoniae | 3 | 2021 | 76 | 0.180 |
Why?
|
| Bacteriological Techniques | 1 | 2021 | 87 | 0.180 |
Why?
|
| Enterovirus | 2 | 2008 | 52 | 0.180 |
Why?
|
| Disease Susceptibility | 4 | 2019 | 299 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 1117 | 0.170 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2020 | 59 | 0.170 |
Why?
|
| Treatment Outcome | 13 | 2022 | 12392 | 0.170 |
Why?
|
| Texas | 12 | 2019 | 3588 | 0.170 |
Why?
|
| DNA, Viral | 6 | 2016 | 480 | 0.170 |
Why?
|
| Hepatitis B virus | 1 | 2021 | 130 | 0.170 |
Why?
|
| Immunity, Mucosal | 3 | 2014 | 87 | 0.170 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 359 | 0.170 |
Why?
|
| Cytokines | 4 | 2020 | 1288 | 0.170 |
Why?
|
| Restaurants | 1 | 2000 | 15 | 0.170 |
Why?
|
| Genome, Viral | 3 | 2020 | 168 | 0.170 |
Why?
|
| Respiratory Tract Diseases | 1 | 2000 | 75 | 0.170 |
Why?
|
| Nasal Mucosa | 5 | 2007 | 66 | 0.170 |
Why?
|
| Injections, Intradermal | 4 | 2015 | 32 | 0.170 |
Why?
|
| Anthrax Vaccines | 1 | 2019 | 26 | 0.160 |
Why?
|
| Meat | 1 | 2000 | 48 | 0.160 |
Why?
|
| Reference Standards | 5 | 2023 | 236 | 0.160 |
Why?
|
| Ceramides | 1 | 2020 | 39 | 0.160 |
Why?
|
| Binding Sites | 5 | 2023 | 1303 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 1697 | 0.160 |
Why?
|
| Anthrax | 1 | 2019 | 31 | 0.160 |
Why?
|
| Travel-Related Illness | 1 | 2019 | 3 | 0.160 |
Why?
|
| Japanese Encephalitis Vaccines | 1 | 2019 | 12 | 0.160 |
Why?
|
| Prevalence | 7 | 2022 | 2458 | 0.160 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 72 | 0.160 |
Why?
|
| Food Contamination | 2 | 2013 | 23 | 0.160 |
Why?
|
| Antigens, Plant | 1 | 2019 | 33 | 0.160 |
Why?
|
| Encephalitis, Japanese | 1 | 2019 | 17 | 0.160 |
Why?
|
| Disasters | 2 | 2019 | 103 | 0.160 |
Why?
|
| Malaria, Vivax | 1 | 1999 | 8 | 0.160 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 174 | 0.160 |
Why?
|
| Learning Curve | 1 | 2019 | 54 | 0.160 |
Why?
|
| Epitope Mapping | 2 | 2020 | 80 | 0.160 |
Why?
|
| Health Facilities | 1 | 2019 | 61 | 0.150 |
Why?
|
| Capsid | 3 | 2023 | 142 | 0.150 |
Why?
|
| Culture Media | 4 | 2024 | 182 | 0.150 |
Why?
|
| Protease Inhibitors | 2 | 2021 | 96 | 0.150 |
Why?
|
| Fungi | 1 | 2019 | 69 | 0.150 |
Why?
|
| Virus Inactivation | 1 | 2018 | 9 | 0.150 |
Why?
|
| Metagenomics | 1 | 2019 | 102 | 0.150 |
Why?
|
| Bacteriophages | 2 | 2020 | 83 | 0.150 |
Why?
|
| Transplants | 1 | 1999 | 35 | 0.150 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 71 | 0.150 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2007 | 345 | 0.150 |
Why?
|
| Cyclonic Storms | 1 | 2019 | 75 | 0.150 |
Why?
|
| Antigens, Helminth | 1 | 2019 | 190 | 0.150 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 298 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2015 | 326 | 0.140 |
Why?
|
| Tularemia | 1 | 2017 | 13 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2015 | 506 | 0.140 |
Why?
|
| Transplant Recipients | 2 | 2016 | 219 | 0.140 |
Why?
|
| Virus Physiological Phenomena | 1 | 2017 | 14 | 0.140 |
Why?
|
| Catheter-Related Infections | 1 | 2019 | 129 | 0.140 |
Why?
|
| Drug Discovery | 1 | 2018 | 171 | 0.140 |
Why?
|
| Mucins | 1 | 2017 | 75 | 0.140 |
Why?
|
| Viral Structural Proteins | 2 | 2014 | 48 | 0.140 |
Why?
|
| Environmental Exposure | 1 | 2019 | 220 | 0.140 |
Why?
|
| Nucleotide Motifs | 1 | 2016 | 43 | 0.130 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 375 | 0.130 |
Why?
|
| Molecular Epidemiology | 4 | 2010 | 155 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2016 | 259 | 0.130 |
Why?
|
| Genes, Reporter | 2 | 2014 | 381 | 0.130 |
Why?
|
| Crystallography, X-Ray | 4 | 2022 | 357 | 0.130 |
Why?
|
| Immune Evasion | 1 | 2016 | 35 | 0.130 |
Why?
|
| Drug Carriers | 1 | 2017 | 100 | 0.130 |
Why?
|
| Ribotyping | 2 | 2015 | 50 | 0.130 |
Why?
|
| Malaria Vaccines | 2 | 2010 | 17 | 0.130 |
Why?
|
| Rimantadine | 2 | 1998 | 2 | 0.130 |
Why?
|
| Mice | 10 | 2024 | 17631 | 0.130 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 2016 | 60 | 0.130 |
Why?
|
| Age Factors | 6 | 2015 | 2823 | 0.130 |
Why?
|
| Hospitals, Teaching | 4 | 2007 | 104 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2005 | 235 | 0.120 |
Why?
|
| Interleukins | 1 | 2016 | 120 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 874 | 0.120 |
Why?
|
| Malaria, Falciparum | 2 | 2010 | 46 | 0.120 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2015 | 20 | 0.120 |
Why?
|
| Spinal Puncture | 1 | 2015 | 52 | 0.120 |
Why?
|
| Bacteremia | 5 | 2008 | 406 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 880 | 0.120 |
Why?
|
| Fluoroquinolones | 2 | 2024 | 93 | 0.120 |
Why?
|
| Nanoparticles | 2 | 2015 | 232 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2016 | 142 | 0.120 |
Why?
|
| Viral Fusion Proteins | 1 | 2015 | 76 | 0.120 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2015 | 77 | 0.120 |
Why?
|
| Interferon-gamma | 5 | 2015 | 505 | 0.120 |
Why?
|
| Clinical Protocols | 2 | 2023 | 240 | 0.120 |
Why?
|
| Biopsy | 3 | 2016 | 1238 | 0.120 |
Why?
|
| Reproducibility of Results | 5 | 2010 | 2891 | 0.120 |
Why?
|
| Carrier State | 2 | 2001 | 76 | 0.120 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 397 | 0.120 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2014 | 31 | 0.110 |
Why?
|
| Genetic Variation | 2 | 2019 | 1502 | 0.110 |
Why?
|
| Sepsis | 1 | 2019 | 481 | 0.110 |
Why?
|
| beta-Lactamases | 1 | 2016 | 198 | 0.110 |
Why?
|
| Mexico | 4 | 2021 | 182 | 0.110 |
Why?
|
| Luciferases | 1 | 2014 | 131 | 0.110 |
Why?
|
| Intracranial Hypertension | 1 | 2015 | 125 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2020 | 3465 | 0.110 |
Why?
|
| Seawater | 2 | 2022 | 12 | 0.110 |
Why?
|
| Seafood | 1 | 2013 | 7 | 0.110 |
Why?
|
| Aging | 1 | 2020 | 1181 | 0.110 |
Why?
|
| Glucans | 1 | 2013 | 11 | 0.110 |
Why?
|
| Mannans | 1 | 2013 | 11 | 0.110 |
Why?
|
| Blotting, Western | 5 | 2016 | 1102 | 0.110 |
Why?
|
| Binding Sites, Antibody | 3 | 2020 | 99 | 0.110 |
Why?
|
| Ribavirin | 2 | 1992 | 79 | 0.110 |
Why?
|
| Lung | 2 | 2012 | 1496 | 0.110 |
Why?
|
| Ligands | 2 | 2011 | 539 | 0.110 |
Why?
|
| Helium | 1 | 2013 | 10 | 0.110 |
Why?
|
| Plasmids | 1 | 2014 | 513 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 1726 | 0.100 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2013 | 68 | 0.100 |
Why?
|
| Nasal Lavage Fluid | 1 | 2013 | 14 | 0.100 |
Why?
|
| Dose-Response Relationship, Immunologic | 4 | 2008 | 108 | 0.100 |
Why?
|
| Species Specificity | 4 | 2014 | 550 | 0.100 |
Why?
|
| Respiratory System | 1 | 1993 | 97 | 0.100 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2013 | 35 | 0.100 |
Why?
|
| Staphylococcal Infections | 2 | 2008 | 561 | 0.100 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2013 | 81 | 0.100 |
Why?
|
| HIV Infections | 3 | 2022 | 1899 | 0.100 |
Why?
|
| Secretory Pathway | 1 | 2012 | 12 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2015 | 168 | 0.100 |
Why?
|
| Tuberculosis | 2 | 2013 | 526 | 0.100 |
Why?
|
| Risk Factors | 10 | 2024 | 10315 | 0.100 |
Why?
|
| Elephants | 1 | 2013 | 40 | 0.100 |
Why?
|
| Surface Plasmon Resonance | 2 | 2014 | 47 | 0.100 |
Why?
|
| Haemophilus influenzae | 2 | 2003 | 130 | 0.100 |
Why?
|
| Single-Blind Method | 2 | 2020 | 239 | 0.100 |
Why?
|
| Renal Dialysis | 1 | 2019 | 855 | 0.100 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 1897 | 0.100 |
Why?
|
| Cryptococcosis | 2 | 2005 | 42 | 0.100 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2012 | 37 | 0.100 |
Why?
|
| Primary Health Care | 3 | 2024 | 771 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2005 | 267 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2013 | 141 | 0.100 |
Why?
|
| Infant, Newborn | 7 | 2022 | 8233 | 0.100 |
Why?
|
| Clostridium Infections | 1 | 2015 | 245 | 0.100 |
Why?
|
| Disease Vectors | 1 | 2011 | 24 | 0.090 |
Why?
|
| Acute Disease | 7 | 2014 | 1111 | 0.090 |
Why?
|
| Incidence | 3 | 2020 | 3147 | 0.090 |
Why?
|
| Measles | 1 | 1992 | 41 | 0.090 |
Why?
|
| Crassostrea | 1 | 2011 | 4 | 0.090 |
Why?
|
| Protein Array Analysis | 1 | 2021 | 101 | 0.090 |
Why?
|
| Gene Products, env | 1 | 1991 | 15 | 0.090 |
Why?
|
| Interleukin-4 | 3 | 2010 | 140 | 0.090 |
Why?
|
| Dexamethasone | 2 | 2022 | 276 | 0.090 |
Why?
|
| Patient Acuity | 1 | 2020 | 66 | 0.090 |
Why?
|
| Dendritic Cells | 2 | 2010 | 414 | 0.090 |
Why?
|
| alpha-Tocopherol | 2 | 2024 | 38 | 0.090 |
Why?
|
| Australia | 1 | 2010 | 137 | 0.090 |
Why?
|
| Hepatitis A | 2 | 2001 | 32 | 0.090 |
Why?
|
| Cluster Analysis | 2 | 2010 | 398 | 0.090 |
Why?
|
| Opportunistic Infections | 3 | 2002 | 78 | 0.090 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 66 | 0.080 |
Why?
|
| Protein Precursors | 1 | 1991 | 152 | 0.080 |
Why?
|
| Enzyme Inhibitors | 2 | 2006 | 581 | 0.080 |
Why?
|
| Injections, Subcutaneous | 3 | 2017 | 130 | 0.080 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2020 | 91 | 0.080 |
Why?
|
| Cysteine Endopeptidases | 1 | 2010 | 114 | 0.080 |
Why?
|
| Europe | 1 | 2010 | 354 | 0.080 |
Why?
|
| Pneumonia | 3 | 2010 | 325 | 0.080 |
Why?
|
| Drug Combinations | 2 | 2024 | 267 | 0.080 |
Why?
|
| Protein Conformation | 2 | 2021 | 834 | 0.080 |
Why?
|
| Peptides | 1 | 2013 | 811 | 0.080 |
Why?
|
| Pandemics | 2 | 2020 | 1107 | 0.080 |
Why?
|
| Protozoan Proteins | 1 | 2010 | 111 | 0.080 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2013 | 383 | 0.080 |
Why?
|
| Chlamydia | 1 | 1989 | 3 | 0.080 |
Why?
|
| ISCOMs | 1 | 2009 | 3 | 0.080 |
Why?
|
| Mycoplasma pneumoniae | 1 | 1989 | 12 | 0.080 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 1989 | 13 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 3425 | 0.080 |
Why?
|
| Surface-Active Agents | 1 | 2009 | 33 | 0.080 |
Why?
|
| Kobuvirus | 1 | 2008 | 2 | 0.080 |
Why?
|
| Emulsions | 1 | 2009 | 69 | 0.080 |
Why?
|
| Chlamydia Infections | 1 | 1989 | 49 | 0.080 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2003 | 207 | 0.080 |
Why?
|
| Cattle | 3 | 2013 | 568 | 0.070 |
Why?
|
| Oxygen | 2 | 2022 | 556 | 0.070 |
Why?
|
| Common Cold | 2 | 2015 | 23 | 0.070 |
Why?
|
| Kinetics | 2 | 2023 | 1333 | 0.070 |
Why?
|
| Prospective Studies | 8 | 2015 | 6153 | 0.070 |
Why?
|
| Rabies Vaccines | 2 | 2013 | 11 | 0.070 |
Why?
|
| Protein Domains | 2 | 2021 | 236 | 0.070 |
Why?
|
| DNA, Bacterial | 2 | 2007 | 478 | 0.070 |
Why?
|
| Safety | 2 | 2006 | 217 | 0.070 |
Why?
|
| HIV-1 | 2 | 1992 | 465 | 0.070 |
Why?
|
| Liposomes | 1 | 2009 | 188 | 0.070 |
Why?
|
| Methicillin Resistance | 1 | 2008 | 118 | 0.070 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2007 | 92 | 0.070 |
Why?
|
| Respiration, Artificial | 2 | 2020 | 473 | 0.070 |
Why?
|
| DNA Fingerprinting | 1 | 2007 | 107 | 0.070 |
Why?
|
| Bacterial Typing Techniques | 1 | 2007 | 102 | 0.070 |
Why?
|
| Peritonitis | 1 | 2007 | 74 | 0.070 |
Why?
|
| Swine | 2 | 2022 | 1210 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 472 | 0.070 |
Why?
|
| Paramyxoviridae Infections | 2 | 2005 | 47 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 3 | 2014 | 767 | 0.070 |
Why?
|
| Abscess | 1 | 2008 | 137 | 0.070 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2007 | 147 | 0.070 |
Why?
|
| Cephalosporins | 1 | 1987 | 137 | 0.070 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1992 | 455 | 0.070 |
Why?
|
| Phenotype | 4 | 2024 | 4262 | 0.070 |
Why?
|
| Tetanus Toxoid | 2 | 2013 | 45 | 0.070 |
Why?
|
| Variola virus | 2 | 2007 | 4 | 0.070 |
Why?
|
| France | 3 | 2013 | 80 | 0.070 |
Why?
|
| Birds | 2 | 2020 | 85 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2023 | 2820 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 1203 | 0.070 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2007 | 133 | 0.070 |
Why?
|
| Macrophages | 1 | 2010 | 625 | 0.060 |
Why?
|
| Sequence Alignment | 3 | 2014 | 620 | 0.060 |
Why?
|
| Foodborne Diseases | 2 | 2010 | 11 | 0.060 |
Why?
|
| Interleukin-10 | 2 | 1997 | 174 | 0.060 |
Why?
|
| Levivirus | 1 | 2005 | 3 | 0.060 |
Why?
|
| Drug Resistance, Viral | 1 | 2006 | 47 | 0.060 |
Why?
|
| Hemagglutinins, Viral | 2 | 1996 | 25 | 0.060 |
Why?
|
| Escherichia coli Infections | 1 | 2008 | 189 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 2 | 1996 | 257 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2000 | 1324 | 0.060 |
Why?
|
| RNA-Directed DNA Polymerase | 2 | 1997 | 46 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 2008 | 207 | 0.060 |
Why?
|
| Drug Design | 1 | 2006 | 152 | 0.060 |
Why?
|
| Plasmodium falciparum | 2 | 2010 | 64 | 0.060 |
Why?
|
| Virus Assembly | 1 | 2005 | 47 | 0.060 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 365 | 0.060 |
Why?
|
| Haemophilus Infections | 2 | 2003 | 91 | 0.060 |
Why?
|
| Metapneumovirus | 1 | 2005 | 51 | 0.060 |
Why?
|
| Medical Staff | 1 | 2004 | 7 | 0.060 |
Why?
|
| Logistic Models | 4 | 2015 | 1810 | 0.060 |
Why?
|
| Germany | 1 | 2004 | 65 | 0.060 |
Why?
|
| Glycomics | 1 | 2024 | 15 | 0.060 |
Why?
|
| Glycopeptides | 1 | 2024 | 28 | 0.060 |
Why?
|
| Drug Resistance, Multiple | 1 | 2024 | 48 | 0.060 |
Why?
|
| Glycosylation | 1 | 2024 | 125 | 0.060 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2024 | 43 | 0.050 |
Why?
|
| Ciprofloxacin | 1 | 2024 | 66 | 0.050 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2003 | 9 | 0.050 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2003 | 15 | 0.050 |
Why?
|
| Patients | 1 | 2004 | 120 | 0.050 |
Why?
|
| Cell Culture Techniques | 2 | 2016 | 281 | 0.050 |
Why?
|
| Mali | 1 | 2023 | 9 | 0.050 |
Why?
|
| Gambia | 1 | 2023 | 28 | 0.050 |
Why?
|
| Chemokines, CXC | 1 | 2003 | 38 | 0.050 |
Why?
|
| Environmental Monitoring | 2 | 2005 | 65 | 0.050 |
Why?
|
| Kenya | 1 | 2023 | 52 | 0.050 |
Why?
|
| Clathrin | 1 | 2023 | 24 | 0.050 |
Why?
|
| Neutrophil Infiltration | 1 | 2003 | 64 | 0.050 |
Why?
|
| Hemagglutination | 1 | 2003 | 8 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2022 | 6 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2001 | 258 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 69 | 0.050 |
Why?
|
| Pyridines | 1 | 2024 | 230 | 0.050 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2002 | 53 | 0.050 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2003 | 63 | 0.050 |
Why?
|
| Hospitals, Urban | 3 | 1999 | 97 | 0.050 |
Why?
|
| Amebiasis | 1 | 2002 | 10 | 0.050 |
Why?
|
| Brucellosis | 1 | 2002 | 19 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 64 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2003 | 209 | 0.050 |
Why?
|
| Typhoid Fever | 1 | 2002 | 19 | 0.050 |
Why?
|
| Laboratory Personnel | 1 | 2022 | 3 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2023 | 1898 | 0.050 |
Why?
|
| Smallpox | 1 | 2002 | 10 | 0.050 |
Why?
|
| Aerosols | 3 | 1992 | 65 | 0.050 |
Why?
|
| Biguanides | 1 | 2022 | 13 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2022 | 32 | 0.050 |
Why?
|
| Neurocysticercosis | 1 | 2002 | 27 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2023 | 284 | 0.050 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2002 | 53 | 0.050 |
Why?
|
| Singapore | 1 | 2021 | 16 | 0.050 |
Why?
|
| Glycoconjugates | 1 | 2021 | 7 | 0.050 |
Why?
|
| Polyproteins | 1 | 2021 | 8 | 0.050 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2021 | 13 | 0.050 |
Why?
|
| Hemagglutinins | 1 | 2021 | 23 | 0.050 |
Why?
|
| Cell Survival | 1 | 2024 | 813 | 0.050 |
Why?
|
| Rabies virus | 1 | 2001 | 4 | 0.050 |
Why?
|
| Emigration and Immigration | 1 | 2002 | 80 | 0.050 |
Why?
|
| Milk, Human | 1 | 2025 | 300 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2004 | 320 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 1693 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2021 | 37 | 0.050 |
Why?
|
| Bronchitis, Chronic | 1 | 2001 | 18 | 0.050 |
Why?
|
| Models, Biological | 2 | 2020 | 1460 | 0.050 |
Why?
|
| Transcriptome | 2 | 2020 | 954 | 0.050 |
Why?
|
| Lymphocyte Activation | 3 | 2010 | 701 | 0.050 |
Why?
|
| Malaria | 1 | 2002 | 86 | 0.050 |
Why?
|
| Viral Tropism | 2 | 2013 | 43 | 0.050 |
Why?
|
| Human Experimentation | 2 | 2012 | 36 | 0.050 |
Why?
|
| Japan | 1 | 2021 | 133 | 0.050 |
Why?
|
| Spinal Cord Injuries | 1 | 2004 | 313 | 0.050 |
Why?
|
| DNA-Directed RNA Polymerases | 2 | 2005 | 121 | 0.050 |
Why?
|
| Cells, Cultured | 4 | 2012 | 3056 | 0.050 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 140 | 0.040 |
Why?
|
| Cell Surface Display Techniques | 1 | 2020 | 10 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2021 | 158 | 0.040 |
Why?
|
| Genomic Library | 1 | 2020 | 42 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2024 | 797 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 249 | 0.040 |
Why?
|
| Viral Load | 2 | 2014 | 387 | 0.040 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 22 | 0.040 |
Why?
|
| Inflammation | 2 | 2005 | 1446 | 0.040 |
Why?
|
| Proteomics | 1 | 2024 | 502 | 0.040 |
Why?
|
| Th2 Cells | 2 | 2012 | 185 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 2001 | 396 | 0.040 |
Why?
|
| Feedback | 1 | 2021 | 164 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 150 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 3348 | 0.040 |
Why?
|
| Glycochenodeoxycholic Acid | 1 | 2020 | 8 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2022 | 389 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 143 | 0.040 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2019 | 11 | 0.040 |
Why?
|
| Macaca mulatta | 2 | 2002 | 491 | 0.040 |
Why?
|
| Merozoite Surface Protein 1 | 1 | 1999 | 10 | 0.040 |
Why?
|
| Phylogeny | 2 | 2014 | 696 | 0.040 |
Why?
|
| Emergency Responders | 1 | 2019 | 17 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 5176 | 0.040 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2020 | 41 | 0.040 |
Why?
|
| DNA, Complementary | 2 | 2014 | 462 | 0.040 |
Why?
|
| Amines | 1 | 1999 | 36 | 0.040 |
Why?
|
| Rabbits | 1 | 2020 | 718 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 251 | 0.040 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2019 | 36 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1999 | 80 | 0.040 |
Why?
|
| Invasive Fungal Infections | 1 | 2019 | 13 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 695 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2019 | 34 | 0.040 |
Why?
|
| Respirovirus | 1 | 1999 | 4 | 0.040 |
Why?
|
| Coronaviridae | 1 | 1998 | 4 | 0.040 |
Why?
|
| Hemolymph | 1 | 1998 | 3 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1999 | 125 | 0.040 |
Why?
|
| History, 17th Century | 1 | 1999 | 35 | 0.040 |
Why?
|
| History, Ancient | 1 | 1999 | 53 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 2913 | 0.040 |
Why?
|
| Urban Health | 1 | 1998 | 78 | 0.040 |
Why?
|
| Adenoviruses, Human | 1 | 1999 | 81 | 0.040 |
Why?
|
| Chlorine | 1 | 2018 | 15 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 3157 | 0.040 |
Why?
|
| Lung Diseases, Fungal | 1 | 1998 | 32 | 0.040 |
Why?
|
| Alcohols | 1 | 2018 | 18 | 0.040 |
Why?
|
| Gene Expression | 1 | 2003 | 1560 | 0.040 |
Why?
|
| Amantadine | 1 | 1998 | 10 | 0.040 |
Why?
|
| History, 19th Century | 1 | 1999 | 116 | 0.040 |
Why?
|
| Mother-Child Relations | 1 | 2019 | 77 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 118 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 92 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 290 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 216 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 1998 | 391 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2002 | 1020 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2018 | 200 | 0.040 |
Why?
|
| Case-Control Studies | 5 | 2004 | 3299 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 254 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 136 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 369 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 589 | 0.040 |
Why?
|
| Agglutination Tests | 1 | 2017 | 9 | 0.040 |
Why?
|
| Vero Cells | 2 | 2012 | 109 | 0.040 |
Why?
|
| Seroconversion | 1 | 2017 | 14 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 1056 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2018 | 291 | 0.040 |
Why?
|
| Retrospective Studies | 6 | 2019 | 16353 | 0.030 |
Why?
|
| Medication Systems, Hospital | 1 | 1997 | 42 | 0.030 |
Why?
|
| Cysticercosis | 1 | 1997 | 22 | 0.030 |
Why?
|
| Equivalence Trials as Topic | 1 | 2017 | 12 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 292 | 0.030 |
Why?
|
| Viral Plaque Assay | 1 | 2017 | 42 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2015 | 1259 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 1997 | 68 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1172 | 0.030 |
Why?
|
| History, 20th Century | 1 | 1999 | 381 | 0.030 |
Why?
|
| Health Personnel | 1 | 2022 | 507 | 0.030 |
Why?
|
| Granuloma | 1 | 1997 | 68 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 289 | 0.030 |
Why?
|
| Hospitals | 2 | 2015 | 390 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1438 | 0.030 |
Why?
|
| Immunity | 1 | 1998 | 192 | 0.030 |
Why?
|
| DNA Probes | 1 | 1996 | 123 | 0.030 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 1997 | 87 | 0.030 |
Why?
|
| Hot Temperature | 1 | 1997 | 137 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1997 | 244 | 0.030 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2016 | 63 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 1997 | 116 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 1999 | 316 | 0.030 |
Why?
|
| Hybridomas | 1 | 2016 | 42 | 0.030 |
Why?
|
| Forced Expiratory Volume | 2 | 2003 | 171 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2016 | 118 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2016 | 73 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1996 | 289 | 0.030 |
Why?
|
| Antigens | 1 | 2016 | 156 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2016 | 100 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 1998 | 224 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2016 | 295 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2016 | 59 | 0.030 |
Why?
|
| Diagnosis | 1 | 1996 | 29 | 0.030 |
Why?
|
| Mothers | 1 | 2019 | 355 | 0.030 |
Why?
|
| In Situ Hybridization | 3 | 2003 | 471 | 0.030 |
Why?
|
| Enterocytes | 1 | 2016 | 74 | 0.030 |
Why?
|
| Autopsy | 1 | 1996 | 113 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2016 | 1197 | 0.030 |
Why?
|
| Granzymes | 1 | 2015 | 37 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 658 | 0.030 |
Why?
|
| Antibodies, Protozoan | 2 | 2010 | 76 | 0.030 |
Why?
|
| Acclimatization | 1 | 1995 | 14 | 0.030 |
Why?
|
| RNA | 2 | 1998 | 570 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1025 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 119 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 1999 | 780 | 0.030 |
Why?
|
| Dogs | 1 | 1996 | 775 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2015 | 50 | 0.030 |
Why?
|
| Genes | 1 | 2016 | 447 | 0.030 |
Why?
|
| Cold Temperature | 1 | 1995 | 78 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 238 | 0.030 |
Why?
|
| Virosomes | 1 | 2014 | 4 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 528 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 2014 | 39 | 0.030 |
Why?
|
| Coronavirus 229E, Human | 1 | 1994 | 2 | 0.030 |
Why?
|
| Coronavirus OC43, Human | 1 | 1994 | 4 | 0.030 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Copepoda | 1 | 2014 | 6 | 0.030 |
Why?
|
| Hospitals, University | 2 | 2009 | 97 | 0.030 |
Why?
|
| Enzyme Precursors | 1 | 2014 | 25 | 0.030 |
Why?
|
| Coronavirus | 1 | 1994 | 25 | 0.030 |
Why?
|
| Infection Control | 2 | 2010 | 156 | 0.030 |
Why?
|
| Crystallography | 1 | 2014 | 40 | 0.030 |
Why?
|
| Th1 Cells | 2 | 2010 | 153 | 0.030 |
Why?
|
| Staphylococcus aureus | 2 | 2008 | 462 | 0.030 |
Why?
|
| COS Cells | 1 | 2014 | 274 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2012 | 997 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 573 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2014 | 96 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1997 | 504 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2014 | 211 | 0.030 |
Why?
|
| Liver | 1 | 2021 | 1748 | 0.030 |
Why?
|
| Dimerization | 1 | 2014 | 144 | 0.030 |
Why?
|
| HIV Antibodies | 2 | 1992 | 69 | 0.030 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 616 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 175 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2014 | 122 | 0.030 |
Why?
|
| Serum Albumin, Bovine | 1 | 2013 | 48 | 0.030 |
Why?
|
| Cell Aggregation | 1 | 2013 | 25 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2014 | 173 | 0.030 |
Why?
|
| Muramidase | 1 | 2013 | 94 | 0.030 |
Why?
|
| Surface Properties | 1 | 2013 | 83 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2107 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2015 | 1699 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2012 | 104 | 0.030 |
Why?
|
| Graft Survival | 1 | 2015 | 538 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 2012 | 93 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 2174 | 0.020 |
Why?
|
| HIV Antigens | 1 | 1992 | 12 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 69 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2012 | 4404 | 0.020 |
Why?
|
| Sputum | 2 | 2003 | 106 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1016 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 435 | 0.020 |
Why?
|
| AIDS Vaccines | 1 | 1992 | 30 | 0.020 |
Why?
|
| Bronchoscopy | 2 | 2003 | 153 | 0.020 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1992 | 44 | 0.020 |
Why?
|
| Prognosis | 2 | 2015 | 4645 | 0.020 |
Why?
|
| Obstetric Labor, Premature | 1 | 1992 | 85 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2011 | 98 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2015 | 590 | 0.020 |
Why?
|
| Viral Envelope Proteins | 1 | 2012 | 152 | 0.020 |
Why?
|
| Static Electricity | 1 | 2011 | 45 | 0.020 |
Why?
|
| Eosinophils | 1 | 2012 | 118 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 296 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 880 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2013 | 314 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 772 | 0.020 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 1991 | 6 | 0.020 |
Why?
|
| Molecular Typing | 1 | 2011 | 34 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1991 | 107 | 0.020 |
Why?
|
| Air Microbiology | 1 | 1990 | 11 | 0.020 |
Why?
|
| Digestive System | 1 | 2011 | 63 | 0.020 |
Why?
|
| Abortion, Spontaneous | 1 | 1992 | 78 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2248 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 1992 | 114 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 1328 | 0.020 |
Why?
|
| Aluminum Compounds | 1 | 2010 | 17 | 0.020 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2010 | 10 | 0.020 |
Why?
|
| Hemocytes | 1 | 2010 | 4 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2023 | 4534 | 0.020 |
Why?
|
| Proteins | 1 | 2016 | 1036 | 0.020 |
Why?
|
| Maximal Midexpiratory Flow Rate | 1 | 1990 | 3 | 0.020 |
Why?
|
| Outpatients | 2 | 2006 | 256 | 0.020 |
Why?
|
| Half-Life | 1 | 1990 | 158 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2010 | 51 | 0.020 |
Why?
|
| Particle Size | 1 | 1990 | 124 | 0.020 |
Why?
|
| Sequence Homology | 1 | 2010 | 63 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2010 | 44 | 0.020 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2010 | 38 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2010 | 59 | 0.020 |
Why?
|
| Vital Capacity | 1 | 1990 | 76 | 0.020 |
Why?
|
| Phosphates | 1 | 2010 | 113 | 0.020 |
Why?
|
| Guatemala | 1 | 2010 | 63 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 1990 | 199 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2010 | 149 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2010 | 101 | 0.020 |
Why?
|
| HIV Seropositivity | 1 | 1991 | 121 | 0.020 |
Why?
|
| Geography | 1 | 2010 | 113 | 0.020 |
Why?
|
| Mutation | 2 | 2018 | 5845 | 0.020 |
Why?
|
| India | 1 | 2010 | 211 | 0.020 |
Why?
|
| Cholera Toxin | 1 | 2009 | 49 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2013 | 1017 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2009 | 149 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 1396 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 983 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 212 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 1992 | 592 | 0.020 |
Why?
|
| Spinal Diseases | 1 | 2008 | 45 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2008 | 19 | 0.020 |
Why?
|
| Hospitals, County | 1 | 2008 | 23 | 0.020 |
Why?
|
| DEAD Box Protein 58 | 1 | 2007 | 12 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 2 | 1998 | 194 | 0.020 |
Why?
|
| Rescue Work | 1 | 2007 | 11 | 0.020 |
Why?
|
| Nasal Cavity | 1 | 1987 | 50 | 0.020 |
Why?
|
| Allantois | 1 | 2007 | 1 | 0.020 |
Why?
|
| Chorion | 1 | 2007 | 8 | 0.020 |
Why?
|
| Biological Warfare | 1 | 2007 | 3 | 0.020 |
Why?
|
| Chemical Warfare Agents | 1 | 2007 | 6 | 0.020 |
Why?
|
| Relief Work | 1 | 2007 | 31 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2007 | 112 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2007 | 131 | 0.020 |
Why?
|
| Administration, Oral | 2 | 1999 | 684 | 0.020 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2007 | 121 | 0.020 |
Why?
|
| Chemokines | 1 | 2007 | 133 | 0.020 |
Why?
|
| Bronchiolitis | 1 | 2007 | 122 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2005 | 97 | 0.020 |
Why?
|
| Comorbidity | 2 | 2003 | 1534 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 2522 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 1069 | 0.020 |
Why?
|
| Mesocricetus | 1 | 2005 | 72 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2005 | 261 | 0.010 |
Why?
|
| Cricetinae | 1 | 2005 | 422 | 0.010 |
Why?
|
| Point Mutation | 1 | 2006 | 348 | 0.010 |
Why?
|
| Trauma Severity Indices | 1 | 2004 | 86 | 0.010 |
Why?
|
| Pancreas | 1 | 2005 | 221 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2004 | 29 | 0.010 |
Why?
|
| Neoplasms | 1 | 1999 | 2790 | 0.010 |
Why?
|
| Ribonucleosides | 1 | 1983 | 15 | 0.010 |
Why?
|
| Sex Factors | 1 | 2008 | 1289 | 0.010 |
Why?
|
| Respirovirus Infections | 1 | 1983 | 19 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 2003 | 30 | 0.010 |
Why?
|
| Chemokine CXCL5 | 1 | 2003 | 6 | 0.010 |
Why?
|
| Bronchiolitis, Viral | 1 | 1983 | 30 | 0.010 |
Why?
|
| Pseudomonas aeruginosa | 2 | 1997 | 164 | 0.010 |
Why?
|
| Pharynx | 1 | 2003 | 66 | 0.010 |
Why?
|
| Disease Transmission, Infectious | 1 | 2004 | 84 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 144 | 0.010 |
Why?
|
| Laboratories | 1 | 2004 | 81 | 0.010 |
Why?
|
| Pan troglodytes | 1 | 2003 | 71 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 315 | 0.010 |
Why?
|
| Respiratory Mucosa | 1 | 2003 | 91 | 0.010 |
Why?
|
| Drug Stability | 1 | 2002 | 58 | 0.010 |
Why?
|
| Temperature | 1 | 2003 | 307 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2003 | 443 | 0.010 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2001 | 23 | 0.010 |
Why?
|
| Propiolactone | 1 | 2001 | 1 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2005 | 320 | 0.010 |
Why?
|
| Chromatography | 1 | 2001 | 44 | 0.010 |
Why?
|
| Erythema | 1 | 2001 | 24 | 0.010 |
Why?
|
| Lymphadenitis | 1 | 2001 | 26 | 0.010 |
Why?
|
| Pruritus | 1 | 2001 | 41 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2007 | 829 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2005 | 940 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 1420 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2001 | 459 | 0.010 |
Why?
|
| Headache | 1 | 2001 | 107 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 867 | 0.010 |
Why?
|
| Food Handling | 1 | 2000 | 18 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2000 | 106 | 0.010 |
Why?
|
| Oseltamivir | 1 | 1999 | 16 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 1360 | 0.010 |
Why?
|
| Universities | 1 | 2000 | 125 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 1121 | 0.010 |
Why?
|
| Skin Tests | 1 | 1999 | 78 | 0.010 |
Why?
|
| Nasopharynx | 1 | 1999 | 79 | 0.010 |
Why?
|
| Cryptococcus neoformans | 1 | 1998 | 21 | 0.010 |
Why?
|
| Pain | 1 | 2001 | 451 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1999 | 729 | 0.010 |
Why?
|
| Enterobacter cloacae | 1 | 1997 | 12 | 0.010 |
Why?
|
| Acinetobacter | 1 | 1997 | 7 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2000 | 872 | 0.010 |
Why?
|
| Communicable Disease Control | 1 | 1997 | 138 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1998 | 575 | 0.010 |
Why?
|
| Community-Acquired Infections | 1 | 1997 | 241 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2007 | 1825 | 0.010 |
Why?
|
| Leukemia | 1 | 1998 | 372 | 0.010 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 1994 | 20 | 0.010 |
Why?
|
| Haplorhini | 1 | 1994 | 123 | 0.010 |
Why?
|
| Cause of Death | 1 | 1996 | 476 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 1997 | 493 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1399 | 0.010 |
Why?
|
| Otitis Externa | 1 | 1992 | 5 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1992 | 36 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1996 | 334 | 0.010 |
Why?
|
| Cell-Free System | 1 | 1992 | 105 | 0.010 |
Why?
|
| Empyema | 1 | 1992 | 24 | 0.010 |
Why?
|
| Cellulitis | 1 | 1992 | 62 | 0.010 |
Why?
|
| Leukocytes | 1 | 1992 | 211 | 0.010 |
Why?
|
| Monocytes | 1 | 1992 | 345 | 0.010 |
Why?
|
| Nose | 1 | 1983 | 94 | 0.000 |
Why?
|
| Random Allocation | 1 | 1983 | 441 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1983 | 1099 | 0.000 |
Why?
|